3654 results for «209»

Filter By

3654 results

Calcified lesions: when one dedicated device is not enough

22 May 2026 – From EuroPCR 2026

This session highlights the need for multiple dedicated devices in the treatment of calcified coronary lesions. It discusses combined orbital and rotational atherectomy techniques, debulking in complex high-risk patients, and the integration of atherectomy with intravascular lithotripsy systems. Emphasis is placed on physiology and imaging-guided approaches...

Innovative strategies in STEMI management

22 May 2026 – From EuroPCR 2026

This session presents innovative strategies in STEMI management, including the treatment of acute saphenous vein graft occlusion, primary PCI via the left internal mammary artery, and a two-step lesion debulking approach. It also covers hybrid drug-coated balloon strategies in complex multivessel disease and the emerging role...

Imaging-guided CTO PCI

21 May 2026 – From EuroPCR 2026

This session focuses on imaging-guided CTO PCI, presenting cases that illustrate the utility of OCT, CT, and IVUS for lesion assessment and procedural guidance. Topics include woven-like CTOs, double CTO evaluation, management of late stent malapposition, and strategies for navigating complex occlusions to optimize outcomes.

Challenging cases in calcified lesions PCI

22 May 2026 – From EuroPCR 2026

This session addresses challenging cases in PCI of heavily calcified lesions. It covers unexpected complications such as silent shockwave failures, interventions in calcified Kawasaki disease, delayed coronary obstructions post-TAVI, and complex left main bifurcation lesions. The session underscores the perseverance required to successfully navigate these demanding...

Novel indications for DCB

21 May 2026 – From EuroPCR 2026

This session reviews emerging clinical applications for drug-coated balloons (DCB) beyond traditional indications. It covers outcomes in venous stenosis, aorto-ostial lesions, and coronary bifurcation disease, comparing DCB strategies with drug-eluting stents and highlighting recent clinical trial findings.

New frontiers in coronary disease treatment

21 May 2026 – From EuroPCR 2026

Examine recent advances in coronary disease treatment focusing on drug-eluting stents versus drug-coated balloon strategies. This session presents real-world data on lesion preparation, sex-specific outcomes, physiological disease patterns, and procedural factors influencing PCI success.

TAVI in small annuli - Small anatomies, big challenges

21 May 2026 – From EuroPCR 2026

This session addresses the challenges of transcatheter aortic valve implantation (TAVI) in patients with small aortic annuli. It features registry data comparing valve types, evaluates long-term outcomes, prosthesis-patient mismatch implications, and regional variations in clinical and quality-of-life outcomes.

Refining PCI plannings and decision-making with novel technologies

21 May 2026 – From EuroPCR 2026

This session highlights cutting-edge technologies that enhance PCI planning and decision-making. It covers the clinical populations benefiting from QFR-guided revascularisation, prognostic insights from radial wall strain in DCB-treated vessels, and advances in artificial intelligence and machine learning to assess ischemia and predict PCI outcomes, especially in...

MASTER-DAPT: “the MASTER of high-bleeding risk trials”

28 Aug 2021

Marco Valgimigli (Lugano, Switzerland) presented the results of the MASTER DAPT trial on Saturday, August 28, in a Hot Line session of the ESC Congress 2021. Luis G. Ortega-Paz provides his PICOT & SWOT analysis of this study.

Luis Ortega-Paz

Author

Luis Ortega-Paz
ESC Congress 2021 - MASTER-DAPT : “the MASTER of high-bleeding risk trials”

On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

05 Mar 2023

Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

SMT’s Hydra TAVR Valve demonstrates sustained safety, durability, and hemodynamic performance at 5 Years

19 Nov 2025

TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

04 Nov 2024

Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.

Also watch the interview with Susheel K. Kodali

Alessandro Sticchi

Author

Alessandro Sticchi
TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR

29 Mar 2025

Daniele Giacoppo and Nicola Ammirabile provide their take on the main results of the HOST-BR trial, presented by Hyo-Soo Kim at ACC.25 in Chicago.

Nicola Ammirabile

Author

Nicola Ammirabile
Daniele Giacoppo

Author

Daniele Giacoppo
Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR

HOST-EXAM:10-year follow-up of clopidogrel vs aspirin monotherapy in stable CAD after PCI with drug-eluting stent

30 Mar 2026

Nicola Ryan provides her take on the 10-year follow-up of the HOST-EXAM, which was presented by Hyo-Soo Kim at ACC.26 in New Orleans.

Nicola Ryan

Author

Nicola Ryan
10-year follow-up of clopidogrel vs aspirin monotherapy in stable coronary artery disease after percutaneous coronary intervention with drug-eluting stent
Didn’t find what you were looking for?